Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Palivizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Palivizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Palivizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Palivizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Palivizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Palivizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Palivizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Palivizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Palivizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Palivizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Palivizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Palivizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Palivizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Palivizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Palivizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Palivizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Palivizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Palivizumab. |
| Equol | Equol may increase the thrombogenic activities of Palivizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Palivizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Palivizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Palivizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Palivizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Palivizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Palivizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Palivizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Palivizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Palivizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Palivizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Palivizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Palivizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Palivizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Palivizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Palivizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Palivizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Palivizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Palivizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Palivizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Palivizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Palivizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Palivizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Palivizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Palivizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Palivizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Palivizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Palivizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Palivizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Palivizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Daclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bevacizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Technetium Tc-99m arcitumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Panitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ranibizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Palivizumab is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Palivizumab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Palivizumab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Palivizumab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Palivizumab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Palivizumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Palivizumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Palivizumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Palivizumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Palivizumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Palivizumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Palivizumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Palivizumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Palivizumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Canakinumab. |